Clinical trial • Phase I • Neurology

NRG5051 for Parkinson's disease | Amyotrophic lateral sclerosis

Phase I trial of NRG5051 for Parkinson's disease | Amyotrophic lateral sclerosis. 118 participants.

Overview

Trial Therapeutic Area
Neurology
Trial Disease
Parkinson's disease | Amyotrophic lateral sclerosis
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
06-10-2025
First CTIS Authorization Date
17-11-2025

Trial design

Phase I trial across 1 site in Netherlands.

Target Sample Size
118

Eligibility

Recruits 118 Vulnerable population not selected (isVulnerablePopulationSelected=false); no consent or assent handling information provided in the record..

Vulnerable Population
Vulnerable population not selected (isVulnerablePopulationSelected=false); no consent or assent handling information provided in the record.

Recruitment

Planned Sample Size
118
Recruitment Window Months
11

Geography

Total Number Of Sites
1
Total Number Of Participants
118

Netherlands

Earliest CTIS Part Ii Submission Date
12-11-2025
Latest Decision Or Authorization Date
10-03-2026
Processing Time Days
118
Number Of Sites
1
Number Of Participants
118

Sites

Site Name
Centre for Human Drug Research
Department Name
Neurology
Contact Person Name
Philip Kremer
Contact Person Email
cta@chdr.nl

Sponsor

Primary sponsor

Full Name
Nrg Therapeutics Limited
Organisation Type
Pharmaceutical company
Country Of Registered Address
United Kingdom

Investigational products

Investigational Product Name
NRG5051

Related trials

Other published trials that may interest you.